CA2705105A1 - Pharmaceutical composition for cancer treatment - Google Patents

Pharmaceutical composition for cancer treatment Download PDF

Info

Publication number
CA2705105A1
CA2705105A1 CA2705105A CA2705105A CA2705105A1 CA 2705105 A1 CA2705105 A1 CA 2705105A1 CA 2705105 A CA2705105 A CA 2705105A CA 2705105 A CA2705105 A CA 2705105A CA 2705105 A1 CA2705105 A1 CA 2705105A1
Authority
CA
Canada
Prior art keywords
interferon
ifn
receptor
alpha
type
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2705105A
Other languages
English (en)
French (fr)
Inventor
Ignacio Javier Melero Bermejo
Juan Dubrot Armendariz
Sandra Hervas Stubbs
Agnes Laurence Le Bon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Proyecto de Biomedicina CIMA SL
Institut National de la Sante et de la Recherche Medicale INSERM
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2705105A1 publication Critical patent/CA2705105A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7156—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA2705105A 2007-11-07 2008-11-07 Pharmaceutical composition for cancer treatment Abandoned CA2705105A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ES200702961A ES2336873B1 (es) 2007-11-07 2007-11-07 Composicion farmaceutica para el tratamiento de cancer.
ES200702961.P 2007-11-07
PCT/ES2008/000693 WO2009060112A1 (es) 2007-11-07 2008-11-07 Composición farmacéutica para el tratamiento de cáncer

Publications (1)

Publication Number Publication Date
CA2705105A1 true CA2705105A1 (en) 2009-05-14

Family

ID=40351964

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2705105A Abandoned CA2705105A1 (en) 2007-11-07 2008-11-07 Pharmaceutical composition for cancer treatment

Country Status (11)

Country Link
US (1) US20110059045A1 (https=)
EP (1) EP2223701A1 (https=)
JP (1) JP2011503039A (https=)
CN (1) CN101951955A (https=)
AU (1) AU2008324056A1 (https=)
BR (1) BRPI0820351A2 (https=)
CA (1) CA2705105A1 (https=)
ES (1) ES2336873B1 (https=)
MX (1) MX2010005086A (https=)
RU (1) RU2010122934A (https=)
WO (1) WO2009060112A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014005091A2 (pt) 2011-09-05 2017-06-13 Beijing Hanmi Pharmaceutical Co Ltd composição farmacêutica para o tratamento do câncer compreendendo conjugado de interferon alfa
CN104684923B (zh) 2012-07-13 2018-09-28 株式会社新日本科学 手性核酸佐剂
TWI718086B (zh) * 2013-01-07 2021-02-11 英屬維爾京群島商遠東超級實驗室有限公司 通過干擾素的經皮和/或經粘膜給藥治療骨癌、皮膚癌、皮下癌、粘膜癌和/或粘膜下癌的方法和組合物
EP3082839A4 (en) * 2013-12-20 2017-08-09 National University of Singapore Differentiation therapy with cd137 ligand agonists
WO2016156291A1 (en) * 2015-03-31 2016-10-06 F. Hoffmann-La Roche Ag Antigen binding molecules comprising a trimeric tnf family ligand
CN111511762B (zh) 2017-08-21 2025-05-06 天演药业公司 抗cd137分子及其用途
WO2019104716A1 (en) * 2017-12-01 2019-06-06 Adagene Inc. Methods for using cd137 ligand as biomarker for treatment with anti-cd137 antibody
WO2019148444A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Anti-ctla4 antibodies and methods of making and using the same
WO2019148445A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Precision/context-dependent activatable antibodies, and methods of making and using the same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040197312A1 (en) * 2003-04-02 2004-10-07 Marina Moskalenko Cytokine-expressing cellular vaccine combinations
WO2006088447A1 (en) * 2005-02-15 2006-08-24 Gtc Biotherapeutics, Inc. An anti-cd137 antibody as an agent in the treatement of cancer and glycosylation variants thereof
KR20080068089A (ko) * 2005-10-21 2008-07-22 지티씨바이오쎄라퓨틱스,인크. 항체 의존성 세포 독성 활성이 증강된 항체, 그 생산 및사용 방법

Also Published As

Publication number Publication date
US20110059045A1 (en) 2011-03-10
EP2223701A1 (en) 2010-09-01
MX2010005086A (es) 2010-08-10
BRPI0820351A2 (pt) 2015-10-27
JP2011503039A (ja) 2011-01-27
ES2336873A1 (es) 2010-04-16
ES2336873B1 (es) 2011-01-24
WO2009060112A1 (es) 2009-05-14
AU2008324056A1 (en) 2009-05-14
RU2010122934A (ru) 2011-12-20
CN101951955A (zh) 2011-01-19

Similar Documents

Publication Publication Date Title
US20110059045A1 (en) Pharmaceutical composition for cancer treatment
US9844582B2 (en) Synergistic tumor treatment with extended-PK IL-2 and therapeutic agents
RU2604814C2 (ru) Варианты гуманизированных иммуномодулирующих моноклональных антител
JP4494977B2 (ja) Ｇｄ２に結合するマウス１４．１８抗体のヒト化抗体（ｈ１４．１８）およびそのｉｌ−２融合タンパク質
US20250215414A1 (en) Combination cancer immunotherapies with arginine depletion agents
US20040176576A1 (en) Antibodies against cancer
JP6682438B2 (ja) 癌治療のための改善された細胞組成物および方法
CN117304342B (zh) 嵌合抗原受体及其应用
US20090123413A1 (en) Use of bat monoclonal antibody for immunotherapy
KR20100113572A (ko) 항-ＥＤｂ 피브로넥틴 항체-ＩＬ-２ 융합 단백질과 Ｂ 세포, Ｂ 세포 전구체 및/또는 이의 암성 대응물에 결합하는 분자의 조합물
JP2022548364A (ja) 免疫療法のエンハンサーとして有用なｉｌ－１０／ｆｃ融合タンパク質
US10308697B2 (en) Fusion proteins for treating cancer and related methods
US20250099542A1 (en) Method of treating a tumor with a combination of il-7 protein and vegf antagonist
WO2002091996A2 (en) Methods for treating cancer
CN115006517A (zh) Il-21-抗白蛋白单域抗体融合蛋白药物组合物及其用途
CN114053403A (zh) 融合蛋白在制备疫苗佐剂或预防和治疗病毒感染的药物中的用途
JP2020150947A (ja) 抗ポドプラニン抗体
KR101482957B1 (ko) 상피 성장 인자 수용체 항체에 대항하는 항체 치료의 효과를 개선하기 위한 치료 조성물
US20250145680A1 (en) Novel interferon variants and bifunctional fusion molecules thereof
JP6737482B1 (ja) 抗ポドプラニン抗体
JP2025521387A (ja) 抗－ｃｄ７３抗体およびｉｌ－２を含む融合タンパク質およびその用途
HK40080422A (en) Il-21-anti-albumin single-domain antibody fusion protein pharmaceutical composition and use thereof
Amedei et al. Cancer Immunotherapy: The Share of Cytokines and Chemokines
WO2009101225A1 (es) Composición farmacéutica para el tratamiento del cáncer
HK1140697A (en) Therapeutic compositions for boosting the effect of antibody therapy against the epidermal growth factor receptor

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20131107